• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Suppression of histamine-induced wheal response by loratadine (SCH 29851) over 28 days in man.

作者信息

Roman I J, Kassem N, Gural R P, Herron J

出版信息

Ann Allergy. 1986 Oct;57(4):253-6.

PMID:2945499
Abstract

Five groups of 12 healthy volunteers each received in double-blind, randomized fashion oral b.i.d. doses of 10, 20, or 40 mg loratadine, 12 mg chlorpheniramine maleate (CTM), or placebo for 28 days. Histamine and saline were injected intradermally into opposite arms at baseline and at specified times following treatment on days 1, 3, 7, 14, 21, and 28. Notable suppression of adjusted wheal formation (histamine-induced minus saline-induced) occurred within two hours after the first dose of each active treatment on day 1. In general, throughout the treatment period, suppression of adjusted wheal formation by all doses of loratadine was significantly greater than by placebo. Suppression by 10 mg loratadine was comparable to CTM, and 20 and 40 mg loratadine were significantly greater than CTM. Suppression of wheal formation by loratadine during the treatment period and during five days posttreatment were dose related. The continued effectiveness of loratadine throughout the 28 days suggests that tolerance to loratadine did not develop in this study. Sedation occurred in 8 of 12 subjects receiving CTM, 1 of 12 receiving 10 mg loratadine, and 1 of 12 receiving placebo.

摘要

相似文献

1
Suppression of histamine-induced wheal response by loratadine (SCH 29851) over 28 days in man.
Ann Allergy. 1986 Oct;57(4):253-6.
2
Effects of loratadine (SCH 29851) in suppression of histamine-induced skin wheals.氯雷他定(SCH 29851)对组胺诱导的皮肤风团的抑制作用。
Ann Allergy. 1988 Jun;60(6):505-7.
3
Relative potency of fexofenadine HCl 180 mg, loratadine 10 mg, and placebo using a skin test model of wheal-and-flare suppression.使用风团和潮红抑制皮肤试验模型评估180毫克盐酸非索非那定、10毫克氯雷他定和安慰剂的相对效价。
Ann Allergy Asthma Immunol. 2003 Jun;90(6):629-34. doi: 10.1016/S1081-1206(10)61867-4.
4
Inhibition of the histamine wheal by ebastine compared with cetirizine, fexofenadine and loratadine at steady state.与西替利嗪、非索非那定和氯雷他定稳态时相比,依巴斯汀对组胺风团的抑制作用。
Drugs Exp Clin Res. 2002;28(6):243-7.
5
Evaluation of inhibition of wheal response to histamine by multiple doses of terfenadine.多剂量特非那定对组胺所致风团反应抑制作用的评估。
Ann Allergy. 1989 Dec;63(6 Pt 2):609-11.
6
Comparative efficacy of bilastine, desloratadine and rupatadine in the suppression of wheal and flare response induced by intradermal histamine in healthy volunteers.比拉斯汀、地氯雷他定和卢帕他定对健康志愿者皮内注射组胺所致风团和潮红反应抑制作用的疗效比较
Curr Med Res Opin. 2017 Jan;33(1):129-136. doi: 10.1080/03007995.2016.1240665. Epub 2016 Oct 21.
7
Pharmacologic evaluation of loratadine (SCH 29851), chlorpheniramine and placebo.
Eur J Clin Pharmacol. 1986;31(2):247-50. doi: 10.1007/BF00606669.
8
Comparison of the effects of desloratadine and levocetirizine on histamine-induced wheal, flare and itch in human skin.地氯雷他定和左西替利嗪对组胺诱导的人体皮肤风团、潮红及瘙痒作用的比较。
Inflamm Res. 2003 Oct;52(10):424-7. doi: 10.1007/s00011-003-1193-5.
9
Comparative study of SCH 434 and CTM-D in the treatment of seasonal allergic rhinitis.SCH 434与中药复方D治疗季节性变应性鼻炎的对比研究。
Clin Ther. 1994 Jan-Feb;16(1):50-6.
10
Comparative wheal and flare study of mizolastine vs terfenadine, cetirizine, loratadine and placebo in healthy volunteers.咪唑斯汀与特非那定、西替利嗪、氯雷他定及安慰剂在健康志愿者中的风团及红晕对比研究。
Br J Clin Pharmacol. 1995 Nov;40(5):459-65.

引用本文的文献

1
High-risks drug adverse events associated with Cetirizine and Loratadine for the treatment of allergic diseases: A retrospective pharmacovigilance study based on the FDA adverse event reporting system database.西替利嗪和氯雷他定治疗过敏性疾病的高风险药物不良事件:一项基于美国食品药品监督管理局不良事件报告系统数据库的回顾性药物警戒研究
Clin Transl Allergy. 2024 Sep;14(9):e12392. doi: 10.1002/clt2.12392.
2
Antihistamines and allergy.抗组胺药与过敏
Aust Prescr. 2018 Apr;41(2):41-45. doi: 10.18773/austprescr.2018.013. Epub 2018 Apr 3.
3
Predicting and establishing the clinical efficacy of a histamine h(1)-receptor antagonist : desloratadine, the model paradigm.
预测和确立一种组胺 H(1)-受体拮抗剂的临床疗效:地氯雷他定,作为典范。
Clin Drug Investig. 2005;25(3):153-64. doi: 10.2165/00044011-200525030-00001.
4
Second-generation antihistamines: actions and efficacy in the management of allergic disorders.第二代抗组胺药:在过敏性疾病管理中的作用与疗效
Drugs. 2005;65(3):341-84. doi: 10.2165/00003495-200565030-00004.
5
Clinical pharmacology of new histamine H1 receptor antagonists.新型组胺H1受体拮抗剂的临床药理学
Clin Pharmacokinet. 1999 May;36(5):329-52. doi: 10.2165/00003088-199936050-00003.
6
Comparative tolerability of second generation antihistamines.第二代抗组胺药的耐受性比较
Drug Saf. 1999 May;20(5):385-401. doi: 10.2165/00002018-199920050-00001.
7
Loratadine. A review of recent findings in pharmacology, pharmacokinetics, efficacy, and safety, with a look at its use in combination with pseudoephedrine.氯雷他定。药理学、药代动力学、疗效及安全性方面近期研究成果综述,兼论其与伪麻黄碱联合应用情况。
Clin Rev Allergy. 1993 Spring;11(1):89-110. doi: 10.1007/BF02802295.
8
Loratadine. A reappraisal of its pharmacological properties and therapeutic use in allergic disorders.氯雷他定:对其药理特性及在过敏性疾病治疗应用的重新评估
Drugs. 1994 Oct;48(4):617-37. doi: 10.2165/00003495-199448040-00009.
9
Optimum pharmacological management of chronic rhinitis.慢性鼻炎的最佳药物治疗
Drugs. 1989 Aug;38(2):313-31. doi: 10.2165/00003495-198938020-00010.
10
Suppression of histamine-induced skin reactions by loratadine and cetirizine diHCl.氯雷他定和盐酸西替利嗪对组胺诱导的皮肤反应的抑制作用。
Eur J Clin Pharmacol. 1989;36(6):617-9. doi: 10.1007/BF00637746.